# Medherant announces positive Phase I results for its first transdermal drug delivery patch
Author:  Pal Sinha, Barnali 
Author URL: https://financedigest.com/author/pal-sinha-barnali
Published: 2018-11-22
Category: TECHNOLOGY
Category URL: https://financedigest.com/category/technology
Meta Title: Medherant Completes Successful Phase I Studies for
Meta Description: Medherant, a leading innovator in transdermal drug delivery, has achieved positive results in Phase I trials for its novel Ibuprofen TEPI Patch. Learn more.
URL: https://financedigest.com/medherant-announces-positive-phase-i-results-for-its-first-transdermal-drug-delivery-patchhtml

![undefined](https://prod.superblogcdn.com/site_cuid_cm5qst7v3003gwirgwqtxn8i8/images/fd130318-12-1736840204893-compressed.jpg)

National investment group Mercia Technologies PLC, one of the UK’s most active technology investors, is pleased to announce that its direct investment Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI® Patch.

![Nigel Davis](https://prod.superblogcdn.com/site_cuid_cm5qst7v3003gwirgwqtxn8i8/images/nigel-davis-450x300-1736840204949-compressed.jpg)

Nigel Davis

The TEPI Patch was shown to be well tolerated by all subjects in a study of skin irritation and sensitisation. This marks the first clinical safety evaluation of Medherant’s novel adhesive, facilitating the development of the next generation of drug-in-adhesive patches.

In the second study, concentrations of ibuprofen in the blood following repeated application of the Ibuprofen TEPI Patch and a single oral dose of ibuprofen were compared. As expected, blood levels were significantly lower after application of the patch reflecting its design as a local delivery mechanism. Local application provides site-specific pain relief and a lower blood concentration will help minimise side effects.

![Dr Mark Payton](https://prod.superblogcdn.com/site_cuid_cm5qst7v3003gwirgwqtxn8i8/images/dr-mark-payton-450x300-1736840204858-compressed.jpg)

Dr Mark Payton

**Nigel Davis, CEO of Medherant, commented:** “These positive Phase I results signify a major milestone in the ongoing development of our TEPI Patch drug delivery technology and demonstrate that our novel adhesive can be used safely. The successful completion of these trials is a testament to our team’s hard work and dedication. We look forward to taking the Ibuprofen TEPI Patch into Phase III clinical testing.”

**Dr Mark Payton, CEO of Mercia, said:**“This is one of a portfolio of products under development and is a testament to a solid team with a robust proprietary platform technology.”

The company will be seeking Series A finance to support its Phase III Ibuprofen TEPI Patch study and to take its portfolio of TEPI Patch products, which includes a cannabinoid and patches for Alzheimer’s disease, into clinical development.


---
This blog is powered by Superblog. Visit https://superblog.ai to know more.
---